+

ALLERGY in ICD-11

TENTH EDITION, MAY 2019

The  Joint  Allergy  Academies  executive  committees:  -­‐ European  Academy  of  Allergy  and  Clinical  Immunology  (EAACI):  Ioana  Agache,  Antonella  Muraro,  

Nikolaos  G.  Papadopoulos,  Peter  Hellings,  Marek  Jutel  -­‐ World  Allergy  Organization  (WAO):  Lanny  Rosenwasser,  Mario  Sanchez-­‐Borges,  Ignacio  Ansotegui,  

Motohiro  Ebisawa  -­‐ American  Academy  of  Allergy  Asthma  and  Immunology  (AAAAI):  Thomas  Casale,  Robert  Lemanske,  

Thomas  Fleisher,  James  Li,  Robert  A.  Wood,  David  Lang,  David  B.  Peden  -­‐ American  College  of  Allergy,  Asthma  and  Immunology  (ACAAI):  James  Sublet,  Bryan  L.  Martin,  

Bradley  Chipps  -­‐ Asia  Pacific  Association  of  Allergy,  Asthma  and  Clinical  Immunology  (APAAACI):  Hee-­‐Bom  Moon,  

Francis  Thien,  Yoon-­‐Seok  Chang,  Ruby  Pawankar    -­‐ Latin  American  Society  of  Allergy,  Asthma  and  Immunology  (SLAAI):  Juan  Carlos  Sisul,  Edgardo  Jares,  

Maximiliano  Gomez,  Maria  Susana  Repka  de  Ramirez,  João  Tibiriça  -­‐ Patients’  Organization  -­‐ Junior  members  groups  -­‐ The  World  Health  Organization  (WHO)  representatives/  staff  and  WHO-­‐Family  of  International  

Classifications  Network    -­‐ Non-­‐governmental  organizations    

ADRESSED TO:

ALLERGY  IN  ICD-­‐11  NEWSLETTER    LUCIANA  KASE  TANNO,  PASCAL  DEMOLY    

*   Joint   Allergy  Academies:   American  Academy  of   Allergy  Asthma   and   Immunology   (AAAAI),   European  Academy   of   Allergy   and   Clinical   Immunology   (EAACI),   World   Allergy   Organization   (WAO),   American  College   of   Allergy   Asthma   and   Immunology   (ACAAI),   Asia   Pacific   Association   of   Allergy,   Asthma   and  Clinical  Immunology  (APAAACI),  Latin  American  Society  of  Allergy,  Asthma  and  Immunology  (SLAAI)  

The  core  Allergy  in  ICD-­‐11  operational  team  (Luciana  Kase  Tanno  and  Pascal  Demoly),  is  an  independent  group  working  for  the  Allergy  specialty  worldwide  

and  represents  the  Joint  Allergy  Academies*  into  the  ICD-­‐11  and  other  WHO  classifications.  They  are  now  

heading  the  WHO  Collaborating  Centre  on  Classification  Scientific  Support.    

ALLERGY in ICD-11 NEWSLETTER

LUCIANA KASE TANNO, PASCAL DEMOLY

TENTH  EDITION,  MAY  2019  

2

Allergy in ICD-11 TENTH EDITION, MAY 2019

THE  ICD-­‐11  HAS  BEEN  ADOPTED!  

Over  the  last  days,  the  World  Health  Assembly  was  held  in  Geneva,  joining  members  of  states  and  the  WHO  governance.  The  ICD-­‐11  has  been  presented  by  the  WHO  ICD  leadership  and  has  been  fully  endorsed  –  the  ICD-­‐11  was  adopted  on  25th  May  2019!  

It  has  not  been  an  easy  path,  but  now  it  is  real:  we  have  ALLERGY  in  ICD-­‐11!      

It  has  been  a  long  way  with  full  time  efforts  that  we  went  along  together.  We  would  like  thank  very  much  all  who  have  been  supporting  the  ALLERGY  in  ICD-­‐11  initiative!  Trust,  collaboration,  aknowlegement  and  support  were  essential  for  achieving  this  milestone  and  ensuring  a  better  visibility  of  the  Allergy  specialty.  However,  there  is  still  a  long  path  and  we  are  looking  forward  to  many  more  years  of  collaboration!  Let’s  move  forward!  

This  achievement  is  the  outcome  of  many  years  of  unwavering  efforts  of  the  WHO  ICD  Team  together   with   the   great   team   of   experts,   with   whom   we   have   the   pleasure   to   work   with.  CONGRATULATIONS!  

The   recently  designated  WHO  Collaborating  Centre   for  Classification   Scientific   Support,   as   a  member   of   the  WHO  Family   of   International   Classification   (WHO-­‐FIC),  will   play   an   essential  role  to  ensure  a  good  representation  of  allergic  and  hypersensitivity  conditions.  We  count  on  all  our  collaborators!  

The  WHO-­‐  FIC  will  carry  on  working  with  the  WHO  in  order    

to  implement  the  ICD-­‐11  in  different  countries.  

The  full  adoption  of  ICD-­‐11  is  scheduled  to  2022!    

3

Allergy in ICD-11 TENTH EDITION, MAY 2019

The  main  WHO  CC  CSS  tasks  are:    

Ø To   provide   scientific   contribution   for   elaboration  and   conservation   of   the   WHO   products   in   the  domain   of   classification,   terminology   and  standards.  

Ø To   participate   in   continuous   quality   of   the  WHO  products,   in   particular   related   to   definitions,  evaluation   of   end-­‐users   requirements,  conceptions   and   developments   of   trials   and  formation  activities.  

Ø  To  contribute  in  the  development  of  translational  research   with   the   WHO   networks   and   online  platforms.  

WHO COLLABORATING CENTRE FOR CLASSIFICATION SCIENTIFIC SUPPORT

The  World  Health  Organization  has  designated  

the  Department  of  Pulmonology  and  

Addictology,  Division  of  Allergy,  University  Hospital  of  

Montpellier,  as  a  WHO  Collaborating  Centre  for  Classification  Scientific  

Support,  headed  by  Pascal  Demoly  and  Luciana  Kase  

Tanno.  

The heads of the WHO CC Montpellier have been invited to

be part of the WHO-Family of International Classifications

Council.

4

Allergy in ICD-11 TENTH EDITION, MAY 2019

+

GIANA THE GLOBAL INITIATIVE AGAINST ANAPHYLAXIS

Anaphylaxis is a killing hypersensitivity and a public health concern. Anaphylaxis

can be used as a model to promote universal health coverage.

In   June   2018,   the   WHO   established   the   Montpellier  Collaborating   Centre   (CC)   for   Classification   Scientific  Support.  This  designation  came  as  recognition  for  all  the  work   undertaken   as   part   of   the   ‘Allergy   in   ICD-­‐11'  initiative   and   the   CC   is   intended   to   provide   academic,  research   and   scientific   support   to   the   WHO   in   the  implementation,   refinement   and   maintenance   of   the  WHO  classifications.    

As   the   only   WHO   CC   for   classifications   of   allergic   and  hypersensitivity   conditions,  we   also   intend   to   establish  close   collaboration   with   national   bodies   in   order   to  implement  actions  for  better  patients’  care,  monitor  and  prevention,   developments   in   research   and   launch  measures   in  order  to  reduce  avoidable  deaths.  Besides,  to  extend  these  actions  internationally  with  the  support  of   the  WHO-­‐FIC,   academic   and   scientific   networks,   the  Joint   Allergy   Academies,   stakeholders   and   patients’  organizations.   Our   WHO   CC   will   provide   the   means  through   which   governmental   and   nongovernmental  collaborating   parties   can   combine   their   strengths   to  achieve  focused  objectives,  avoiding  wasting  energy  and  resources.   In   this   context,  we   are   launching   the  Global  Initiative   Against   Anaphylaxis   (GIANA),   which   aims   to  achieve  seven  main  goals  in  the  forthcoming  years.    

OBJECTIVE)I)(Epidemiology)-

OBJECTIVE)II)(Burden-of-anaphylaxis)-

OBJECTIVE)III)(Research)-

OBJECTIVE)IV)(Health-care-pathways)-

OBJECTIVE)V)(Awareness)-

OBJECTIVE)VI)(Adrenaline-auto=

injectors)-

OBJECTIVE)VII)(Surveillance)-

Site%coordonnateur% Sites%cons.tu.fs% CCMR%

CARTOGRAPHIE%DU%CRMR%«%ANAFIL%»%

GIANA%Global&Ini*a*ve&Against&

Anaphylaxis&

Tanno%et%al,%2019%

Allergy in ICD-11

NINTH EDITION, OCTOBER 2018

TIMELINE  of  the  ICD-­‐11:  

2019-­‐2022:  IMPLEMENTATION  PROCESS  

-­‐  Translation,  education,  refinements    

-­‐  Inclusion  in  the  national  systems  for  final  use  

**  ALLERGY  in  ICD-­‐11  references:  

 https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1398-­‐9995.2012.02829.x  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405839/pdf/13601_2014_Article_1071.pdf  https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.12386  https://onlinelibrary.wiley.com/doi/full/10.1111/all.12604  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482039/  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630456/  https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.12834  https://www.sciencedirect.com/science/article/pii/S2213219816000210?via%3Dihub  https://www.sciencedirect.com/science/article/pii/S2213219816000507?via%3Dihub  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853516/  https://onlinelibrary.wiley.com/doi/abs/10.1111/all.12945  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967614/  https://onlinelibrary.wiley.com/doi/abs/10.1111/all.13006  https://www.sciencedirect.com/science/article/pii/S2213219816302719?via%3Dihub  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977713/  https://onlinelibrary.wiley.com/doi/abs/10.1111/all.13093  https://www.annallergy.org/article/S1081-­‐1206(16)31273-­‐X/fulltext  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237226/  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301440/  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356259/  https://www.ingentaconnect.com/content/ocean/aap/2017/00000038/00000004%3bjsessionid=t134zldek2bn.x-­‐ic-­‐live-­‐03  https://onlinelibrary.wiley.com/doi/full/10.1111/cea.12973  https://onlinelibrary.wiley.com/doi/full/10.1111/all.13335  https://www.tandfonline.com/doi/full/10.1080/1744666X.2018.1520094  http://www.jiaci.org/ahead-­‐of-­‐print/action-­‐plan-­‐to-­‐reach-­‐the-­‐global-­‐availability-­‐of-­‐adrenaline-­‐auto-­‐injectors  https://insights.ovid.com/pubmed?pmid=30730395  

   

 

   

+